Probiotic Strains Enhancing Intestinal Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for irritable bowel syndrome (IBS) and intestinal disorders lack effective strains of lactic acid bacteria that consistently improve transepithelial resistance, which is crucial for maintaining intestinal barrier integrity and reducing permeability.
Innovation Solution
The use of specific strains of lactobacilli and bifidobacteria, such as DN_116_0044 (CNCM I-4316) and DN_154_0062 (CNCM I-4319), which are selected for their ability to increase transepithelial electric resistance (TEER) and are used in compositions for treating and preventing IBS, IBD, and other intestinal disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotic strains are used, then general intestinal health benefits are provided, but transepithelial resistance is not consistently improved
Solution Approach 1:
The patent applies parameter changes by selecting specific probiotic strains (Lactobacillus rhamnosus DN-116_0044 and Bifidobacterium bifidum DN-154_0062) that have been identified to possess superior TEER-improving properties compared to conventional strains. This selective parameter change in strain identification resolves the contradiction by providing reliable and consistent TEER improvement while maintaining the versatility of having multiple effective strain options available.
2Strength
If intestinal permeability is reduced to improve barrier function, then intestinal barrier integrity is enhanced, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the specific functional property of reducing intestinal permeability from complex probiotic formulations. By identifying and utilizing only the essential TEER-improving strains (Lactobacillus rhamnosus DN-116_0044 and Bifidobacterium bifidum DN-154_0062), the treatment simplifies the approach to enhancing intestinal barrier integrity while maintaining effectiveness, thereby reducing treatment complexity.
3Reliability
If probiotic strains are selected based on TEER improvement capability, then treatment effectiveness for IBS and IBD is enhanced, but strain identification difficulty increases
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing the TEER-improving capabilities of specific probiotic strains (Lactobacillus rhamnosus DN-116_0044 and Bifidobacterium bifidum DN-154_0062) before clinical application. This preliminary characterization work has already been completed and documented, making strain selection straightforward and reducing the difficulty of detecting and measuring effective strains while ensuring treatment effectiveness for IBS and IBD.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacterial strains effectively enhance intestinal barrier integrity, as measured by TEER, providing relief for IBS and IBD symptoms by reducing permeability and improving resistance, even in the presence of damaging agents like LPS.
Implementation Method 1
measuring the difference in potential observed from the apical and basal sides of the monolayer, called the Trans Epithelial Electrical Resistance (TEER)
Data Source
AI summary
The invention relates to the use of lactic acid bacteria, for use in improving transepithelial resistance and more particularly in treating and/or preventing constipation and/or irritable bowel disease.